JP2002529469A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002529469A5 JP2002529469A5 JP2000581028A JP2000581028A JP2002529469A5 JP 2002529469 A5 JP2002529469 A5 JP 2002529469A5 JP 2000581028 A JP2000581028 A JP 2000581028A JP 2000581028 A JP2000581028 A JP 2000581028A JP 2002529469 A5 JP2002529469 A5 JP 2002529469A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- ethyl
- methyl
- compound
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 phenyloxy, benzoxy Chemical group 0.000 description 41
- 125000000217 alkyl group Chemical group 0.000 description 30
- 150000001875 compounds Chemical class 0.000 description 25
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 description 1
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021750 Infantile Spasms Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 241001417524 Pomacanthidae Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 201000006791 West syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 238000004380 ashing Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19095898A | 1998-11-12 | 1998-11-12 | |
| US09/190,958 | 1998-11-12 | ||
| US40074499A | 1999-09-21 | 1999-09-21 | |
| US09/400,744 | 1999-09-21 | ||
| PCT/US1999/026984 WO2000027850A2 (en) | 1998-11-12 | 1999-11-12 | Crf receptor antagonists and methods relating thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002529469A JP2002529469A (ja) | 2002-09-10 |
| JP2002529469A5 true JP2002529469A5 (https=) | 2006-11-24 |
Family
ID=26886600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000581028A Pending JP2002529469A (ja) | 1998-11-12 | 1999-11-12 | Ｃｒｆレセプターアンタゴニストおよびそれに関する方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US6348466B1 (https=) |
| EP (1) | EP1129096B1 (https=) |
| JP (1) | JP2002529469A (https=) |
| KR (1) | KR20010080402A (https=) |
| CN (1) | CN1178941C (https=) |
| AT (1) | ATE240958T1 (https=) |
| AU (1) | AU755997B2 (https=) |
| BR (1) | BR9915129A (https=) |
| CA (1) | CA2349904A1 (https=) |
| DE (1) | DE69908173T2 (https=) |
| DK (1) | DK1129096T3 (https=) |
| ES (1) | ES2196898T3 (https=) |
| HK (1) | HK1038925B (https=) |
| IL (1) | IL143105A0 (https=) |
| NO (1) | NO20012228L (https=) |
| NZ (1) | NZ511267A (https=) |
| PT (1) | PT1129096E (https=) |
| TR (1) | TR200102178T2 (https=) |
| WO (1) | WO2000027850A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2398956A1 (en) * | 2000-02-14 | 2001-08-16 | Japan Tobacco Inc. | A pharmaceutical composition for prophylaxis or therapy of a postoperative stress |
| CA2407597A1 (en) * | 2000-05-01 | 2001-11-08 | Dupont Pharmaceuticals Company | Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists |
| AU2001263329A1 (en) * | 2000-05-18 | 2001-11-26 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods relating thereto |
| ES2207614T3 (es) * | 2000-05-18 | 2004-06-01 | Neurocrine Biosciences, Inc. | Antagonistas del receptor de crf y metodos relacionados con estos. |
| KR20030060927A (ko) * | 2000-11-03 | 2003-07-16 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | Ｃｒｆ 수용체 길항제 및 이와 관련된 방법 |
| WO2002064592A1 (en) * | 2000-12-28 | 2002-08-22 | Neurocrine Biosciences, Inc. | Tricyclic crf receptor antagonists |
| DE60130924T2 (de) | 2000-12-28 | 2008-07-17 | Ono Pharmaceutical Co. Ltd. | Cyclopentaädüpyrazoloä1,5-aüpyrimidin-verbindung als crf-rezeptor antagonist |
| ES2255610T3 (es) | 2001-04-30 | 2006-07-01 | Glaxo Group Limited | Antagonistas de los receptores de crf. |
| GB0117395D0 (en) * | 2001-07-17 | 2001-09-05 | Glaxo Group Ltd | Chemical compounds |
| US7273871B2 (en) | 2001-07-17 | 2007-09-25 | Sb Pharmco Puerto Rico Inc. | Phenyl-5,6,6A,7,8,9-hexahydro-4H-1,4,9-triaza-phenalene derivatives as CRF antagonists |
| CN100422186C (zh) | 2003-06-25 | 2008-10-01 | 小野药品工业株式会社 | 吡唑并嘧啶化合物的甲磺酸盐、其结晶及其制备方法 |
| US20060024661A1 (en) * | 2003-07-30 | 2006-02-02 | The Regents Of The University Of California | Modulation of CRF potentiation of NMDA receptor currents via CRF receptor 2 |
| ATE388150T1 (de) * | 2003-12-22 | 2008-03-15 | Sb Pharmco Inc | Crf-rezeptorantagonisten und diese betreffende verfahren |
| NZ551782A (en) | 2004-06-03 | 2010-03-26 | Athlomics Pty Ltd | Agents and methods for diagnosing stress |
| CA2576435A1 (en) * | 2004-08-09 | 2006-03-23 | Research Development Foundation | Determination of the 3d-structure of an extracellular domain of a b1 g-protein coupled receptor by nmr analysis |
| ES2374773T3 (es) | 2004-08-25 | 2012-02-21 | Ardea Biosciences, Inc. | S-triazolil alfa-mercaptoacetanilidas como inhibidores de la transcriptasa inversa del vih. |
| WO2007050087A1 (en) | 2004-08-25 | 2007-05-03 | Ardea Biosciences, Inc. | N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS |
| WO2006122003A2 (en) | 2005-05-05 | 2006-11-16 | Ardea Biosciences, Inc. | Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv |
| EP2132211A4 (en) | 2006-11-09 | 2011-12-07 | Ardea Biosciences Inc | 4-CYANPHENYLAMINO-SUBSTITUTED BICYCLIC AND HETEROCYCLIC COMPOUNDS AS AN HIV HEMMER |
| JP5099794B2 (ja) | 2007-11-27 | 2012-12-19 | アルデア バイオサイエンシーズ インク． | 新規化合物、組成物、及び使用方法 |
| ES2389752T3 (es) | 2007-12-14 | 2012-10-31 | Ardea Biosciences, Inc. | Inhibidores de la transcriptasa inversa |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4605642A (en) | 1984-02-23 | 1986-08-12 | The Salk Institute For Biological Studies | CRF antagonists |
| US5013737A (en) * | 1988-02-22 | 1991-05-07 | American Cyanamid Company | 2,4,8-Trisubstituted-3H,6H-1,4,5A,8A-tetraazaacenaphtylene-3,5-(4H)-diones and 2,4-8-trisubstituted-4,5-dihydro-5-thioxo-3H,6H-1,4,5A,8A-tetrazaacenaphthylen-3-ones |
| US4904658A (en) | 1988-04-15 | 1990-02-27 | American Cyanamid Company | Substituted-6H,8H-pyrimido-[1,2,3-cd]purine-8,10-(9H)-diones and substituted-6H,10H-pyrimido[1,2-cd]purin-10-ones |
| US5063245A (en) | 1990-03-28 | 1991-11-05 | Nova Pharmaceutical Corporation | Corticotropin-releasing factor antagonism compounds |
| FR2692893B1 (fr) | 1992-06-24 | 1994-09-02 | Sanofi Elf | Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. |
| TW336932B (en) | 1992-12-17 | 1998-07-21 | Pfizer | Amino-substituted pyrazoles |
| DK0674624T3 (da) | 1992-12-17 | 1999-09-13 | Pfizer | Pyrazoler med CRF-antagonistisk aktivitet |
| ATE177101T1 (de) * | 1992-12-17 | 1999-03-15 | Pfizer | Pyrrolopyrimidine als crf antagonisten |
| TW370529B (en) | 1992-12-17 | 1999-09-21 | Pfizer | Pyrazolopyrimidines |
| KR100190730B1 (ko) | 1992-12-17 | 1999-06-01 | 디. 제이. 우드, 스피겔 알렌 제이 | 부신피질 호르몬 유리인자(crf) 길항물질로서 치환된 피라졸 |
| RU2153494C2 (ru) | 1993-10-12 | 2000-07-27 | Дзе Дюпон Мерк Фармасьютикал Компани | 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция |
| TW530047B (en) | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
| WO1995034563A1 (en) | 1994-06-16 | 1995-12-21 | Pfizer Inc. | Pyrazolo and pyrrolopyridines |
| US6020492A (en) | 1995-05-12 | 2000-02-01 | Neurogen Corporation | Deazapurine derivatives; a new class of CRF1 specific ligands |
| FR2735777B1 (fr) | 1995-06-21 | 1997-09-12 | Sanofi Sa | Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant |
| EP0901476A4 (en) | 1996-03-26 | 2001-08-16 | Du Pont Pharm Co | PYRIDINES AND PYRIMIDINES FUSION ARYLOXY AND ARYLTHIO AND DERIVATIVES THEREOF |
| US6107300A (en) | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
| US6326368B1 (en) | 1996-03-27 | 2001-12-04 | Dupont Pharmaceuticals Company | Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof |
| ZA973884B (en) * | 1996-05-23 | 1998-11-06 | Du Pont Merck Pharma | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders |
| HU228962B1 (en) | 1996-07-24 | 2013-07-29 | Bristol Myers Squibb Pharma Co | Azolo triazines, pharmaceutical compositions containing them and use of the compounds |
| US6492520B1 (en) | 1996-08-06 | 2002-12-10 | Pfizer Inc | Substituted pyrido-or pyrimido-containing 6,6- or 6,7-bicyclic derivatives |
| TW477787B (en) | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
| IL127566A0 (en) * | 1996-08-28 | 1999-10-28 | Pfizer | Substituted 6,5-hetero- bicyclic derivatives |
| US6159980A (en) | 1996-09-16 | 2000-12-12 | Dupont Pharmaceuticals Company | Pyrazinones and triazinones and their derivatives thereof |
| FR2754258B1 (fr) | 1996-10-08 | 1998-12-31 | Sanofi Sa | Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant |
| US5760225A (en) | 1996-11-15 | 1998-06-02 | Neurogen Corporation | Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands |
| US5723608A (en) | 1996-12-31 | 1998-03-03 | Neurogen Corporation | 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands |
-
1999
- 1999-11-12 EP EP99961675A patent/EP1129096B1/en not_active Expired - Lifetime
- 1999-11-12 KR KR1020017005818A patent/KR20010080402A/ko not_active Ceased
- 1999-11-12 CA CA002349904A patent/CA2349904A1/en not_active Abandoned
- 1999-11-12 NZ NZ511267A patent/NZ511267A/xx unknown
- 1999-11-12 AU AU18199/00A patent/AU755997B2/en not_active Ceased
- 1999-11-12 AT AT99961675T patent/ATE240958T1/de not_active IP Right Cessation
- 1999-11-12 JP JP2000581028A patent/JP2002529469A/ja active Pending
- 1999-11-12 US US09/439,841 patent/US6348466B1/en not_active Expired - Fee Related
- 1999-11-12 ES ES99961675T patent/ES2196898T3/es not_active Expired - Lifetime
- 1999-11-12 BR BR9915129-4A patent/BR9915129A/pt not_active IP Right Cessation
- 1999-11-12 PT PT99961675T patent/PT1129096E/pt unknown
- 1999-11-12 DE DE69908173T patent/DE69908173T2/de not_active Expired - Lifetime
- 1999-11-12 TR TR2001/02178T patent/TR200102178T2/xx unknown
- 1999-11-12 CN CNB998131725A patent/CN1178941C/zh not_active Expired - Fee Related
- 1999-11-12 IL IL14310599A patent/IL143105A0/xx unknown
- 1999-11-12 DK DK99961675T patent/DK1129096T3/da active
- 1999-11-12 HK HK02100689.4A patent/HK1038925B/en not_active IP Right Cessation
- 1999-11-12 WO PCT/US1999/026984 patent/WO2000027850A2/en not_active Ceased
-
2001
- 2001-05-04 NO NO20012228A patent/NO20012228L/no not_active Application Discontinuation
- 2001-12-20 US US10/027,789 patent/US6723721B2/en not_active Expired - Lifetime
-
2004
- 2004-02-23 US US10/785,386 patent/US20040229879A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002529469A5 (https=) | ||
| JP2007517035A5 (https=) | ||
| JP2002529465A5 (https=) | ||
| JP2006515339A5 (https=) | ||
| JP2021534124A5 (https=) | ||
| WO2004074270A3 (en) | Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same | |
| JP2007502293A5 (https=) | ||
| JP2003520856A5 (https=) | ||
| RU2005106846A (ru) | Производные бензотиазола, характеризующиеся агонистической активностью к бета-2-адренорецепторам | |
| JP2011507849A5 (https=) | ||
| JP2012528166A5 (https=) | ||
| JP2007517044A5 (https=) | ||
| JP2006507355A5 (https=) | ||
| RU2005119633A (ru) | Антивирусные нуклеозидные производные | |
| RU2009132512A (ru) | Аналоги 2-5а и способы их применения | |
| JP2004528334A5 (https=) | ||
| RU2016122908A (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
| JP2006511484A5 (https=) | ||
| JP2022513845A5 (https=) | ||
| CA2584524A1 (en) | Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women | |
| JPWO2003030937A1 (ja) | ミトコンドリアルベンゾジアゼピン受容体アンタゴニストからなるストレス疾患の治療剤 | |
| RU2003115612A (ru) | Производные амидоалкилпиперидинов и амидоалкилпиперазинов, пригодные для лечения нарушений нервной системы | |
| JP2002519325A5 (https=) | ||
| JP2005527542A5 (https=) | ||
| IL283395B2 (en) | Arylmethylureas and substituted heteroarylmethylureas, their analogues and their uses |